Aileron Therapeutics Inc. (ALRN)
NASDAQ: ALRN
· Real-Time Price · USD
2.11
0.18 (9.33%)
At close: Jan 10, 2025, 10:00 PM
Aileron Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | 126K | n/a | n/a | n/a | 134K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | 63K | n/a | 4K | 59K | 52K | 12K | 12K | 43K | 43K | n/a | 42K | 41K | 40K | 39K | 40K | 2K |
Gross Profit | n/a | n/a | 63K | n/a | -4K | -59K | 82K | -12K | -12K | -43K | -43K | n/a | -42K | -41K | -40K | -39K | -40K | -2K |
Operating Income | -6.87M | -5.61M | -42.8M | -6.07M | -9.04M | -7.21M | -7.3M | -1.98M | -1.99M | -5.01M | -4.7M | -6.48M | -8.04M | -8.42M | -6.82M | -6.79M | -6.01M | -6.99M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | 78K | 155K | 112K | 55K | 120K | 110K | 49K | 21K | n/a | 21K | 19K | 14K |
Pretax Income | -6.82M | -5.5M | -40.98M | -5.85M | -8.94M | -7.11M | -7.34M | -1.83M | -1.79M | -4.78M | -4.55M | -6.37M | -7.99M | -8.42M | -6.84M | -6.7M | -5.69M | -6.97M |
Net Income | -6.82M | -5.5M | -40.98M | -5.85M | -8.94M | -7.11M | -7.34M | -1.83M | -1.79M | -4.55M | -4.39M | -6.37M | -7.94M | -8.42M | -6.8M | -6.7M | -5.69M | -6.97M |
Selling & General & Admin | 2.58M | 2.56M | 2.48M | 2.35M | 5.3M | 3.74M | 5.28M | 1.96M | 1.89M | 2.18M | 2.3M | 2.24M | 2.61M | 2.53M | 2.25M | 2.51M | 2.16M | 2.67M |
Research & Development | 4.29M | 3.05M | 3.32M | 3.72M | 3.74M | 3.46M | 1.97M | 22K | 187K | 1.81M | 2.4M | 4.24M | 5.43M | 5.89M | 4.56M | 4.28M | 3.85M | 4.32M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1K | n/a | 177K | n/a | 4K | n/a | -22K | n/a | 66K | n/a | n/a |
Operating Expenses | 6.87M | 5.61M | 5.8M | 6.07M | 9.04M | 7.21M | 7.25M | 1.98M | 2.08M | 3.99M | 4.7M | 6.48M | 8.04M | 8.42M | 6.82M | 6.79M | 6.01M | 6.99M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | -52K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | n/a | 5.86M | 6.07M | 9.04M | 7.21M | 7.3M | 1.98M | 2.08M | 3.99M | 4.7M | 6.48M | 8.04M | 8.42M | 6.82M | 6.79M | 6.01M | 6.99M |
Income Tax Expense | n/a | n/a | 59K | n/a | n/a | -59K | 581K | n/a | n/a | -232K | -156K | n/a | -49K | 1K | 13K | -21K | -19K | n/a |
Shares Outstanding (Basic) | 24.19K | 21.92M | 19.8M | 21.66M | 19.91M | 8.3M | 4.77M | 4.54M | 4.54M | 4.54M | 4.54M | 4.54M | 4.54M | 4.53M | 4.53M | 4.53M | 4.52M | 4.17M |
Shares Outstanding (Diluted) | 24.19K | 21.92M | 19.8M | 21.66M | 19.91M | 8.3M | 4.77M | 4.54M | 4.54M | 4.54M | 4.54M | 4.54M | 4.54M | 4.53M | 4.53M | 4.53M | 4.52M | 4.17M |
EPS (Basic) | -0.28 | -0.25 | -2.07 | -0.27 | -0.45 | -0.86 | -1.54 | -0.4 | -0.39 | -1 | -0.97 | -1.4 | -1.75 | -1.86 | -1.5 | -1.48 | -1.26 | -1.67 |
EPS (Diluted) | -0.28 | -0.25 | -2.07 | -0.27 | -0.45 | -0.86 | -1.54 | -0.4 | -0.39 | -1 | -0.97 | -1.4 | -1.75 | -1.86 | -1.5 | -1.48 | -1.26 | -1.67 |
EBITDA | -6.87M | -5.61M | -40.98M | -6.07M | -9.04M | -7.15M | -7.25M | -1.97M | -2.07M | -3.95M | -4.66M | -6.44M | -8M | -8.38M | -6.78M | -6.75M | -5.97M | -6.99M |
EBIT | n/a | n/a | 22.32M | -6.07M | -9.04M | -7.21M | -7.3M | -1.98M | -2.08M | -3.99M | -4.7M | -6.48M | -8.04M | -8.42M | -6.82M | -6.79M | -6.01M | -6.99M |
Depreciation & Amortization | n/a | n/a | -63K | n/a | 4K | 59K | 52K | 12K | 12K | 43K | 43K | 43K | 42K | 41K | 40K | 39K | 40K | 2K |